Compounds > naxagolide

Page last updated: 2024-08-24

naxagolide and carbidopa

naxagolide has been researched along with carbidopa in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (57.14)	18.7374
1990's	3 (42.86)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ahlskog, JE; Bailey, PA; Miller, PM; Muenter, MD	1
Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ; Tye, S	1
Cedarbaum, JM; Clark, M; Green-Parsons, A; Toy, LH	1
Factor, SA; Sanchez-Ramos, JR; Weiner, WJ	1
Barter, R; Koller, WC; Vetere-Overfield, B	1
Baumann, G; Chin, L; Lieberman, A	1
Critchley, P; Grandas, F; Marsden, CD; Quinn, N; Rohan, A; Stahl, SM	1

Trials

1 trial(s) available for naxagolide and carbidopa

Article	Year
Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa. Clinical neuropharmacology, 1991, Volume: 14, Issue:3 Topics: Adult; Aged; Carbidopa; Delayed-Action Preparations; Dopamine Agents; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Oxazines; Parkinson Disease	1991

Other Studies

6 other study(ies) available for naxagolide and carbidopa

Article	Year
Modulatory role for CCK-B antagonists in Parkinson's disease. Clinical neuropharmacology, 1990, Volume: 13, Issue:4 Topics: Animals; Benzodiazepinones; Carbidopa; Cholecystokinin; Devazepide; Dopamine Agents; Levodopa; Male; Motor Activity; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Phenylurea Compounds; Receptors, Cholecystokinin; Saimiri	1990
Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation. Movement disorders : official journal of the Movement Disorder Society, 1990, Volume: 5, Issue:4 Topics: Activities of Daily Living; Antiparkinson Agents; Brain; Carbidopa; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Oxazines; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D2	1990
The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 1989, Volume: 52, Issue:6 Topics: Antiparkinson Agents; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Oxazines; Parkinson Disease	1989
Tremors in early Parkinson's disease. Clinical neuropharmacology, 1989, Volume: 12, Issue:4 Topics: Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease; Tremor	1989
MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease. Clinical neuropharmacology, 1988, Volume: 11, Issue:3 Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dopamine Agents; Female; Humans; Hypromellose Derivatives; Lactose; Levodopa; Lisuride; Methylcellulose; Middle Aged; Nausea; Oxazines; Parkinson Disease; Pergolide; Psychomotor Performance; Receptors, Dopamine	1988
Antiparkinsonian activity of a single oral dose of PHNO. Movement disorders : official journal of the Movement Disorder Society, 1987, Volume: 2, Issue:1 Topics: Administration, Oral; Adult; Aged; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease, Secondary; Reaction Time	1987